bluebird bio
BLUE
$0.91
Share price
2.50%
Change (1 day)
-79.19%
Change (1 year)
bluebird bio (BLUE) - Cash on Hand
Cash on Hand as of September 2023 : $0.17 B
According to bluebird bio
's latest financial reports the company has $0.17 B in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
bluebird bio - Cash on Hand chart (from 2012 to 2023)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2022-12-31 | $0.18 B | -39.79% |
| 2021-12-31 | $0.29 B | -55.97% |
| 2020-12-31 | $0.68 B | -38.52% |
| 2019-12-31 | $1.10 B | -20.13% |
| 2018-12-31 | $1.38 B | 7.38% |
| 2017-12-31 | $1.29 B | 83.16% |
| 2016-12-31 | $0.70 B | 35.99% |
| 2015-12-31 | $0.51 B | 9.37% |
| 2014-12-31 | $0.47 B | 129.57% |
| 2013-12-31 | $0.20 B | 207.83% |
| 2012-12-31 | $67.01 M | 130.19% |
| 2011-12-31 | $29.11 M |
Cash on Hand for similar companies or competitors
| Company | Cash on Hand | differencediff. | Country |
|---|---|---|---|
 Sanofi SNY | $9.92 B | 5,596.24% | 🇫🇷 France |
 Merck MRK | $7.09 B | 3,969.58% | 🇺🇸 USA |
 Sangamo Therapeutics
SGMO | $81 M | -53.53% | 🇺🇸 USA |
 Acceleron Pharma XLRN | N/A | N/A | 🇺🇸 USA |
 GlycoMimetics
GLYC | $41.79 M | -76.02% | 🇺🇸 USA |
 BioMarin Pharmaceutical BMRN | $1.07 B | 516.09% | 🇺🇸 USA |